Literature DB >> 17848834

Peripheral blood levels of thyroglobulin mRNA and serum thyroglobulin concentrations after radioiodine ablation of multinodular goiter with or without pre-treatment with recombinant human thyrotropin.

I G S Rubio1, M N C Silva, M Knobel, R Romão, R Possato, E M M S Gebrin, C Buchpiguel, G Medeiros-Neto.   

Abstract

We investigated the effect of therapeutic doses of radioiodine (RAI) on peripheral serum messenger thyroglobulin RNA (Tg mRNA) and serum thyroglobulin (sTg) in patients with multinodular goiter (MNG) preceded or not by treatment with recombinant human TSH (rhTSH). Fourteen patients with large MNG (91-542 ml) received RAI (550-2960 MBq). Half of the patients received 0.45 mg of rhTSH prior to the treatment (RAI+rhTSH group) and half did not (RAI group). Patients' blood samples were collected before and 24, 48, and 72 h; 7 and 30 days; and 6, 9, and 12 months after RAI treatment. Serum Tg was measured by immunoradiometric assay, serum anti-Tg by radioimmunoassay, and quantification of circulating Tg mRNA was performed by real-time PCR. The shrinkage of MNG volume was documented by serial computed tomography (CT) scans before, 6 and 12 months after RAI. Peak Tg mRNA and sTg were reached earlier in the RAI+rhTSH group (24 h and 48 h) than in the RAI group (7 days). Both declined after the peak and the lowest levels were observed at 12 months. The mean reduction of the thyroid volume was 19.8% (RAI group) and 30.3% (RAI+rhTSH group) at 6 months (ns) and 32.8% RAI and 52.5% (RAI+rhTSH group) at 12 months (p<0.05). After RAI treatment there was a significant and positive correlation between goiter volume and sTg only in the RAI group (r=0.7; p=0.032). Serum anti-Tg had a transitory and relatively small elevation in 3 and 2 patients, respectively, in the RAI and RAI+rhTSH groups. We concluded that after RAI ablation of MNG there is a rapid release of Tg into the serum possibly from the colloid, which is followed by an elevation of serum Tg mRNA that may be due to an increased release of follicular cells into the blood stream. Both phenomena are enhanced by the use of rhTSH before RAI treatment as a consequence of a more effective and prolonged radiation exposure of the thyroid follicles.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17848834     DOI: 10.1007/BF03346345

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  41 in total

1.  Molecular detection of thyroid cancer: differentiating "signal" and "noise" in clinical assays.

Authors:  Matthew D Ringel
Journal:  J Clin Endocrinol Metab       Date:  2004-01       Impact factor: 5.958

2.  Transient goiter enlargement after administration of 0.3 mg of recombinant human thyrotropin in patients with benign nontoxic nodular goiter: a randomized, double-blind, crossover trial.

Authors:  Viveque Egsgaard Nielsen; Steen J Bonnema; Laszlo Hegedüs
Journal:  J Clin Endocrinol Metab       Date:  2006-01-24       Impact factor: 5.958

3.  Quantitative reverse transcription-PCR measurement of thyroglobulin mRNA in peripheral blood of healthy subjects.

Authors:  S T Wingo; M D Ringel; J S Anderson; A D Patel; Y D Lukes; Y Y Djuh; B Solomon; D Nicholson; P L Balducci-Silano; M A Levine; G L Francis; R M Tuttle
Journal:  Clin Chem       Date:  1999-06       Impact factor: 8.327

4.  Recombinant human thyrotropin is a potent stimulator of thyroid function in normal subjects.

Authors:  L Ramirez; L E Braverman; B White; C H Emerson
Journal:  J Clin Endocrinol Metab       Date:  1997-09       Impact factor: 5.958

5.  Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial.

Authors:  Viveque Egsgaard Nielsen; Steen Joop Bonnema; Henrik Boel-Jørgensen; Peter Grupe; Laszlo Hegedüs
Journal:  Arch Intern Med       Date:  2006-07-24

Review 6.  The effects of recombinant human thyrotropin, in normal subjects and patients with goitre.

Authors:  Viveque Egsgaard Nielsen; Steen Joop Bonnema; Laszlo Hegedüs
Journal:  Clin Endocrinol (Oxf)       Date:  2004-12       Impact factor: 3.478

7.  Human recombinant TSH preceding a therapeutic dose of radioiodine for multinodular goiters has no significant effect in the surge of TSH-receptor and TPO antibodies.

Authors:  Ileana G S Rubio; Bruno H Perone; Marcia N C Silva; Meyer Knobel; Geraldo Medeiros-Neto
Journal:  Thyroid       Date:  2005-02       Impact factor: 6.568

8.  Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.

Authors:  Willy-Anne Nieuwlaat; Ad R Hermus; H Alec Ross; Wilhelmina C Buijs; Michela A Edelbroek; Jo W Bus; Frans H Corstens; Dyde A Huysmans
Journal:  J Nucl Med       Date:  2004-04       Impact factor: 10.057

9.  Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood.

Authors:  M D Ringel; P W Ladenson; M A Levine
Journal:  J Clin Endocrinol Metab       Date:  1998-12       Impact factor: 5.958

10.  Quantitative measurement of thyroglobulin mRNA in peripheral blood of patients after total thyroidectomy.

Authors:  T Takano; A Miyauchi; H Yoshida; Y Hasegawa; K Kuma; N Amino
Journal:  Br J Cancer       Date:  2001-07-06       Impact factor: 7.640

View more
  3 in total

1.  Relationship between circulating anti-thyroglobulin antibodies (TgAb) and tumor metabolism in patients with differentiated thyroid cancer (DTC): prognostic implications.

Authors:  S Morbelli; G Ferrarazzo; E Pomposelli; F Pupo; G Pesce; I Calamia; F Fiz; A Clapasson; M Bauckneht; M Minuto; G Sambuceti; M Giusti; M Bagnasco
Journal:  J Endocrinol Invest       Date:  2016-11-14       Impact factor: 4.256

2.  Evaluation of T cell stimulation by thyrotropin-receptor epitopes in Graves' disease.

Authors:  L J De Groot; Y Ha Shin; D Pan; G Gopalakrishnan; J V Hennessey
Journal:  J Endocrinol Invest       Date:  2009-01       Impact factor: 4.256

3.  Dynamics of serum antithyroglobulin antibodies in patients with differentiated thyroid cancer.

Authors:  Fernanda Bueno; María Gabriela García Falcone; Mirna Angela Peñaloza; Erika Abelleira; Fabián Pitoia
Journal:  Endocrine       Date:  2019-10-24       Impact factor: 3.633

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.